Identification of brain metastasis genes and therapeutic evaluation of histonewas not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/296384 doi: bioRxiv preprint first posted online Apr. 6, 2018; was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/296384 doi: bioRxiv preprint first posted online Apr. 6, 2018; 3 SUMMARY STATEMENT 47We introduce a new syngeneic mouse model of spontaneous breast cancer brain metastasis, 48 demonstrate its phenotypic, functional and transcriptomic relevance to human TNBC brain 49 metastasis and test novel therapies. 50 51 All rights reserved. No reuse allowed without permission.was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/296384 doi: bioRxiv preprint first posted online Apr. 6, 2018; 4 ABSTRACT 52 Breast cancer brain metastasis remains largely incurable. While several mouse models have 53 been developed to investigate the genes and mechanisms regulating breast cancer brain 54 metastasis, these models often lack clinical relevance since they require the use of immune-55 compromised mice and/or are poorly metastatic to brain from the mammary gland. We 56 describe the development and characterisation of an aggressive brain metastatic variant of the 57 4T1 syngeneic model (4T1Br4) that spontaneously metastasises to multiple organs, but is 58 selectively more metastatic to the brain from the mammary gland than parental 4T1 tumours. 59By immunohistochemistry, 4T1Br4 tumours and brain metastases display a triple negative 60 phenotype, consistent with the high propensity of this breast cancer subtype to spread to brain. 61In vitro assays indicate that 4T1Br4 cells have an enhanced ability to adhere to or migrate 62 across a brain-derived endothelial monolayer and greater invasive response to brain- was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which . http://dx.doi.org/10.1101/296384 doi: bioRxiv preprint first posted online Apr. 6, 2018; 5 INTRODUCTION 74Metastasis accounts for the majority of breast cancer-related mortalities and approximately 75 40,000 women were expected to die from the disease in 2017 in the US alone (Ghoncheh et 76 al., 2016). The incidence of brain metastasis in breast cancer patients is estimated at ~30% 77 and is rising, despite more effective systemic therapies (Tabouret et al., 2012). Therapeutic 78 options consist primarily of surgery, whole brain radiation therapy, stereotactic radiosurgery 79 and chemotherapy but these approaches, while extending life, are rarely curative (Eichler et 80 al., 2011). While surgical rese...
Breast cancer brain metastases remain largely incurable. Although several mouse models have been developed to investigate the genes and mechanisms regulating breast cancer brain metastasis, these models often lack clinical relevance since they require the use of immunocompromised mice and/or are poorly metastatic to brain from the mammary gland. We describe the development and characterisation of an aggressive brain metastatic variant of the 4T1 syngeneic model (4T1Br4) that spontaneously metastasises to multiple organs, but is selectively more metastatic to the brain from the mammary gland than parental 4T1 tumours. As seen by immunohistochemistry, 4T1Br4 tumours and brain metastases display a triple-negative phenotype, consistent with the high propensity of this breast cancer subtype to spread to brain. In vitro assays indicate that 4T1Br4 cells have an enhanced ability to adhere to or migrate across a brain-derived endothelial monolayer and greater invasive response to brain-derived soluble factors compared to 4T1 cells. These properties are likely to contribute to the brain selectivity of 4T1Br4 tumours. Expression profiling and gene set enrichment analyses demonstrate the clinical relevance of the 4T1Br4 model at the transcriptomic level. Pathway analyses implicate tumour-intrinsic immune regulation and vascular interactions in successful brain colonisation, revealing potential therapeutic targets. Evaluation of two histone deacetylase inhibitors, SB939 and 1179.4b, shows partial efficacy against 4T1Br4 metastasis to brain and other sites in vivo, and potent radio-sensitising properties in vitro. The 4T1Br4 model provides a clinically relevant tool for mechanistic studies and to evaluate novel therapies against brain metastasis..
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.